March 17, 2016

Not intended for U.S. and UK Media

Bayer Receives FDA Approval for Kovaltry® for the Treatment of Children and Adults with Hemophilia A

Leverkusen, March 17, 2016 - The U.S. Food and Drug Administration today
approved Bayer's Kovaltry® antihemophilic factor VIII (recombinant) for the
treatment of hemophilia A in children and adults. Kovaltry is an unmodified,
full-length recombinant factor VIII product. The approval is based on results
from the LEOPOLD clinical trials, which demonstrated that Kovaltry controls
bleeds, and reduces frequency of bleeding episodes with routine prophylaxis in
children and adults with hemophilia A when used two or three times per week.

"We are proud that, based on our comprehensive development program, physicians
can now consider twice weekly prophylactic treatment with Kovaltry among the
treatment options," said Dr. Joerg Moeller, member of the Executive Committee
of Bayer AG's Pharmaceutical Division and Head of Development. "At Bayer we
have been developing and producing treatments for hemophilia A for more than
two decades."

Bayer recently received approval of Kovaltry in Europe and Canada. Bayer is
pursuing regulatory approvals of Kovaltry for the treatment of hemophilia A in
further markets across the world.

The approvals of Kovaltry build upon Bayer's growing hematology portfolio which
also includes Kogenate® Bayer, a product currently on the market in more than
70 countries, as well as a long-acting recombinant factor VIII pipeline
candidate. Bayer is also pursuing alternative treatment approaches in
preclinical and early clinical development, such as factor VIII gene therapy
and inhibition of tissue factor pathway inhibitor (TFPI) in hemophilia, as well
as in other blood disorders.

About LEOPOLD

The LEOPOLD (Long-Term Efficacy Open-Label Program in Severe Hemophilia A
Disease) Clinical Development Program consists of three multinational clinical
trials designed to evaluate the pharmacokinetics, efficacy and safety of
Kovaltry in subjects with severe hemophilia A (<1% FVIII:C). The combined
trials evaluated Kovaltry in more than 200 children and adults with severe
hemophilia A from 60 sites in 25 countries worldwide.

About Hemophilia

Hemophilia affects approximately 400,000 people around the world and is a
largely inherited disorder in which one of the proteins needed to form blood
clots is missing or reduced. Hemophilia A is the most common type of hemophilia
where factor VIII is missing or reduced. Hemophilia A affects 1 in 10,000
males, including more than 30,000 in Europe, and 16,000 in the U.S. today. Over
time, hemophilia A can cause prolonged or spontaneous bleeding, especially into
the joints, muscles or internal organs.

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the Life Science fields
of health care and agriculture. Its products and services are designed to
benefit people and improve their quality of life. At the same time, the Group
aims to create value through innovation, growth and high earning power. Bayer
is committed to the principles of sustainable development and to its social and
ethical responsibilities as a corporate citizen. In fiscal 2015, the Group
employed around 117,000 people and had sales of EUR 46.3 billion. Capital
expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion.
These figures include those for the high-tech polymers business, which was
floated on the stock market as an independent company named Covestro on October
6, 2015. For more information, go to www.bayer.com.

Our online press service is just a click away: press.bayer.com
Follow us on Facebook: http://www.facebook.com/pharma.bayer
Follow us on Twitter: https://twitter.com/BayerPharma


Find more information at www.bayerpharma.com.


Forward-looking statements

This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer management. Various known and unknown
risks, uncertainties and other factors could lead to material differences
between the actual future results, financial situation, development or
performance of the company and the estimates given here. These factors include
those discussed in Bayer's public reports which are available on the Bayer
website at www.bayer.com. The company assumes no liability whatsoever to update
these forward-looking statements or to conform them to future events or
developments.